For research and educational purposes only. Not medical advice.
CagriSema Reference
Educational, not medical advice reference for CagriSema: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule notes. Also known…
Reference summary
Phase 3 REDEFINE data support investigational status only; no FDA-approved dose should be presented until regulatory status changes.
- Categories
- GLP-1, Fat Loss
- Aliases
- Cagrilintide/semaglutide, CagriSema 2.4 mg/2.4 mg
- Evidence posture
- human — Human trial data exist, but the product remains investigational.
- Regulatory status
- Investigational fixed-dose cagrilintide/semaglutide combination. Novo Nordisk stated CagriSema was not approved in the US or EU at its December 2025 FDA filing announcement.
- Content review status
- investigational verified